Cover Image

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

Abstract The ALK in Lung Cancer Trial of brigAtinib in First Line (ALTA‐1L) compared brigatinib versus crizotinib in anaplastic lymphoma kinase (ALK) inhibitor‐naive patients with ALK+ non‐small cell lung cancer (NSCLC). A population pharmacokinetic (PK) model was used to estimate brigatinib exposur...

Full description

Saved in:

Bibliographic Details
Main Authors:	Neeraj Gupta (Author), Karen L. Reckamp (Author), David R. Camidge (Author), Huub J. Kleijn (Author), Aziz Ouerdani (Author), Francesco Bellanti (Author), John Maringwa (Author), Michael J. Hanley (Author), Shining Wang (Author), Pingkuan Zhang (Author), Karthik Venkatakrishnan (Author)
Format:	Book
Published:	Wiley, 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluation of the drug-drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach
by: Michael J. Hanley, et al.
Published: (2024)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
by: Ali R, et al.
Published: (2019)

Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
by: Mei Elsayed, et al.
Published: (2021)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
by: Uruga H, et al.
Published: (2018)

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report
by: Yadong Wang, et al.
Published: (2021)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017)

Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer
by: Wenjie Liu, et al.
Published: (2024)

Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment
by: Vivek Yadav, et al.
Published: (2024)

Synchronous BRCA2 positive ovarian carcinoma with ALK positive NSCLC: Double trouble
by: Ullas Batra, et al.
Published: (2022)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
by: Xuemin Jiang, et al.
Published: (2021)

Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
by: Dhananjay D. Marathe, et al.
Published: (2023)

Population pharmacokinetics and exposure-response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer
by: Yinhui Liu, et al.
Published: (2024)

Later-Line Treatment with Lorlatinib in <i>ALK</i>- and <i>ROS1</i>-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
by: Maximilian J. Hochmair, et al.
Published: (2020)

Mobocertinib: Mechanism of action, clinical, and translational science
by: Michael J. Hanley, et al.
Published: (2024)

mRNA Expression Level of ALK in Neuroblastoma Is Associated with Histological Subtype, ALK Mutations and ALK Immunohistochemical Protein Expression
by: Rixt S. Bruinsma, et al.
Published: (2024)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
by: Chrisann Kyi, et al.
Published: (2021)

Molecular Analyses
Published: (2022)

Molecular Analyses
Published: (2022)

Activin B can signal through both ALK4 and ALK7 in gonadotrope cells
by: Lee Katharine B, et al.
Published: (2006)

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients
by: Jaydeep K. Srimani, et al.
Published: (2022)

Analyse de l'autorité et autorité de l'analyse
by: Richard Étienne, et al.
Published: (2007)

Hemispheric Anomalies in ADHD: MRI Analyses
by: J Gordon Millichap
Published: (1997)

Spectroscopic Analyses Developments and Applications
Published: (2017)

ALK positive histiocytosis in an adult female with an EML4-ALK RNA fusion
by: Jay Mehta, et al.
Published: (2020)

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
by: Nadia Terranova, et al.
Published: (2022)

Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired compound mutations ALK L1196M and D1203N
by: Na Li, et al.
Published: (2023)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
by: Rijavec E, et al.
Published: (2022)

A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer
by: Silky Bedi, et al.
Published: (2018)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
by: Hong Tao, et al.
Published: (2022)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016)

Les compétences suffisent-elles pour analyser et faire analyser des situations éducatives ?
by: Richard Étienne, et al.
Published: (2008)

Kreativität. Eine philosophische Analyse
by: Mahrenholz, Simone
Published: (2011)

L'analyse, l'archive
by: Élisabeth Roudinesco
Published: (2001)

Ökonomische Analyse politischer Institutionen.
Published: (2010)

Proteomic Analyses of the Vitreous Humour
by: Martina Angi, et al.
Published: (2012)

Analyses of oligodontia phenotypes and genetic etiologies
by: Mengqi Zhou, et al.
Published: (2021)

Pharyngocutaneous Fistula after Laryngectomy: An Umbrella Systematic Review to Uncover Lacunae in Meta-Analyses
by: Karthik Nagaraja Rao, et al.
Published: (2023)

Formulation of Chitosan-Coated Brigatinib Nanospanlastics: Optimization, Characterization, Stability Assessment and In-Vitro Cytotoxicity Activity against H-1975 Cell Lines
by: Randa Mohammed Zaki, et al.
Published: (2022)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
by: David M. Waterhouse, et al.
Published: (2020)

Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations
by: Dalia Elsers, et al.
Published: (2021)